title: Duloxetine: review of its pharmacology, and therapeutic use in depression and other psychiatric disorders.
abstract: BACKGROUND
  The discovery of antidepressant medications has revolutionized the treatment of depression and other psychiatric illnesses. The coming of the selective serotonin (5-HT) reuptake inhibitors (SSRIs) marked a new era in the treatment of depression. These therapies frequently fall short of getting the patient to remission. Agents with a dual action have subsequently been developed which inhibit the reuptake of both 5-HT and NE, getting more patients to remission. Physical symptoms are associated with depression, preventing the patient from obtaining complete recovery. This article provides an overview of the pharmacology, efficacy, and techniques for the clinical use of duloxetine, a dual reuptake inhibitor, which has recently become available.
  
  
  METHODS
  The English literature has been reviewed including both controlled and uncontrolled studies.
  
  
  RESULTS
  Duloxetine is a dual reuptake inhibitor with actions on serotonin as well as norepinephrine. It has been shown to have efficacy in treating depressive symptoms including those with painful physical symptoms. Common side effects include nausea, insomnia, and dizziness.
  
  
  CONCLUSIONS
  The article has been written with clinicians as the target audience, the data suggesting it can be used as a first line agent.
authors.affiliation: Department of Psychiatry, University of Buffalo, School of Medicine, USA. Sgupta1@adelphia.net
authors.forename: Sanjay
authors.initials: S
authors.lastname: Gupta
authors.forename: Nikhil
authors.initials: N
authors.lastname: Nihalani
authors.forename: Prakash
authors.initials: P
authors.lastname: Masand
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003865:Major Depressive Disorder / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D004347:Drug Interactions; D000068736:Duloxetine Hydrochloride; D006207:Half-Life; D006801:Humans; D008657:Metabolic Clearance Rate; D010146:Pain / Q000097:blood / Q000188:drug therapy / Q000523:psychology; D013876:Thiophenes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D013876:Thiophenes; D000068736:Duloxetine Hydrochloride